KAM
CYTK icon

Kazazian Asset Management’s Cytokinetics CYTK Stock Holding History

Kazazian Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,796
Closed -$394K – 54
2025
Q1 		$394K Buy
9,796
+4,560
+87% +$210K 0.32% 36
2024
Q4 		$246K Buy
+5,236
New +$272K 0.19% 46

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Kazazian Asset Management's CYTK Position: Q2 2025 in Review

Kazazian Asset Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 9,796 shares — an estimated $394K sold.

Kazazian Asset Management first reported a position in CYTK in Q4 2024 and held it in 2 quarters. The position peaked at $394K in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • Kazazian Asset Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • Kazazian Asset Management sold 9,796 Cytokinetics shares in Q2 2025, an estimated $394K.
  • Kazazian Asset Management first reported a position in Cytokinetics in Q4 2024 and held it in 2 quarters.
  • Kazazian Asset Management's Cytokinetics position peaked at $394K in Q1 2025.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Kazazian Asset Management's 13F filing for Q2 2025, filed 11 Aug 2025.